KOLLAM: Dally Fernandes (name changed) has been using Semaglutide for the past six months to manage her weight. She believes ...

A new study has found that patients with type 2 diabetes who are not reaching their blood sugar goals on dulaglutide can ...

In recent years, GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have gained attention for their effectiveness in managing diabetes and supporting ...

A study comparing artificial intelligence (AI)-driven clinical recommendations to physician decision-making for common acute complaints in a virtual primary care setting found that AI support has the ...

Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide ...

Findings from the SUMMIT, Altshock-2, and FAIR-HF2 trials were presented at the American College of Cardiology 2025 Annual ...

For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and weight loss compared with ...

For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and weight loss compared with ...

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.

Jim Cramer in a latest program on CNBC urged investors to start accepting the reality of the new economic system under ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the new Donald Trump administration. Health care stocks can often be a solid defensive play in an uncertain economy.